Metformin Inhibits Proliferation and Tumor Growth of QGP-1 Pancreatic Neuroendocrine Tumor Cells by Inducing Cell Cycle Arrest and Apoptosis.
Apoptosis
/ drug effects
Biomarkers
Carcinoma, Neuroendocrine
/ drug therapy
Cell Cycle Checkpoints
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
Humans
Metformin
/ pharmacology
MicroRNAs
/ genetics
Neovascularization, Pathologic
/ drug therapy
Pancreatic Neoplasms
/ drug therapy
Signal Transduction
/ drug effects
Xenograft Model Antitumor Assays
Pancreatic neuroendocrine tumor
apoptosis
cell cycle
metformin
microRNA
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
08
11
2019
revised:
22
11
2019
accepted:
25
11
2019
entrez:
2
1
2020
pubmed:
2
1
2020
medline:
15
1
2020
Statut:
ppublish
Résumé
Pancreatic neuroendocrine tumors (pNETs) are rare pancreatic neoplasms, and therapeutic options for pNETs are limited. Metformin is an anti-hypoglycemic drug that appears to have anticancer effects. However, little is known about the effect of metformin on pNETs. In this study, we investigated the anti-proliferative effect of metformin on a human pNET cell line. The anti-proliferative properties of metformin were evaluated in QGP-1 and NCI-H727 cells using a cell counting kit-8 assay. Xenograft mouse models were used to assess the tumor effect in vivo. Metformin inhibited the proliferation and anti-tumor growth of QGP-1 cells, accompanied by their arrest during the cell cycle at the G Taken together, our study demonstrated the therapeutic potential of metformin and provides molecular mechanistic insights into its anti-tumoral effect on pNETs. This study is the first one describing anti-tumoral effects in pNETs.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Pancreatic neuroendocrine tumors (pNETs) are rare pancreatic neoplasms, and therapeutic options for pNETs are limited. Metformin is an anti-hypoglycemic drug that appears to have anticancer effects. However, little is known about the effect of metformin on pNETs. In this study, we investigated the anti-proliferative effect of metformin on a human pNET cell line.
MATERIALS AND METHODS
METHODS
The anti-proliferative properties of metformin were evaluated in QGP-1 and NCI-H727 cells using a cell counting kit-8 assay. Xenograft mouse models were used to assess the tumor effect in vivo.
RESULTS
RESULTS
Metformin inhibited the proliferation and anti-tumor growth of QGP-1 cells, accompanied by their arrest during the cell cycle at the G
CONCLUSION
CONCLUSIONS
Taken together, our study demonstrated the therapeutic potential of metformin and provides molecular mechanistic insights into its anti-tumoral effect on pNETs. This study is the first one describing anti-tumoral effects in pNETs.
Identifiants
pubmed: 31892560
pii: 40/1/121
doi: 10.21873/anticanres.13933
doi:
Substances chimiques
Biomarkers
0
MicroRNAs
0
Metformin
9100L32L2N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
121-132Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.